On July 1, 2026, Medicare will pay for weight-loss drugs for the first time. The Medicare GLP-1 Bridge is a demonstration program, not permanent coverage, running through December 31, 2027. Eligible beneficiaries pay a flat $50 per month for drugs with list prices between $1,086 and $1,349.
The Ladder
In November 2025, the Trump administration announced pricing agreements with Eli Lilly and Novo Nordisk. Both companies agreed to sell injectable GLP-1 products to Medicare and Medicaid at a net price of $245 per month across all doses. Oral formulations start at $149. The administration launched TrumpRx on February 5, 2026, a direct-to-consumer platform offering cash prices starting at $350 with a glide path to $250.
A study published in JAMA Network Open, led by researchers at Yale and King's College London, calculated the production cost of a month's supply of semaglutide at between 89 cents and $4.73. The disposable pen used to inject it costs more to manufacture than the drug inside it.
Under five dollars to make. $245 to the government. Over a thousand at the pharmacy. The drug is the same molecule at every price point. The price records who was in the room when it was set.
The Selection
KFF estimates 3.8 million Medicare Part D beneficiaries are eligible for the Bridge. The criteria are tiered. A BMI of 35 or higher qualifies on its own. A BMI of 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension on two medications, or chronic kidney disease stage 3a or above. A BMI between 27 and 30 qualifies with prediabetes, a history of heart attack, stroke, or symptomatic peripheral artery disease.
These are not average Medicare recipients. A beneficiary with a BMI of 35 and heart failure costs Medicare more in hospitalizations, cardiac procedures, and joint replacements than in prescriptions. The Bridge, if 50 to 75 percent of eligible beneficiaries participate, costs between $6.7 billion and $10 billion over eighteen months.
The eligibility criteria select for patients whose downstream savings will be largest.
The Bypass
The Bridge was not Plan A. The Treat and Reduce Obesity Act, which would have removed Medicare's statutory exclusion of anti-obesity drugs from Part D, passed the House Ways and Means Committee in 2024 but was never enacted. CMS then designed the BALANCE model, a longer-term framework intended to work through existing Part D insurers. The model required participation from plans covering at least 80 percent of Part D enrollees. UnitedHealth Group and CVS Health declined. CMS delayed the Part D portion of BALANCE indefinitely in April 2026.
So CMS went direct. The Bridge operates under demonstration authority, Section 402 of the Social Security Amendments of 1967. It does not require Congress to change the law or insurers to participate. Fifty-six million people are enrolled in Part D as of February 2026. Congress would not lift the exclusion. The insurers would not administer coverage. The government built around both.
The Regain
The STEP 1 extension trial showed that participants who discontinued semaglutide regained two-thirds of their weight loss within one year. A meta-analysis published in eClinicalMedicine found weight regain reached 60 percent of the original loss at 52 weeks across semaglutide, tirzepatide, and liraglutide. The drugs work while you take them.
The Bridge enrolls patients beginning tomorrow. If a million seniors start GLP-1 therapy at $50 per month and the program expires on schedule, those patients face three paths: pay over a thousand dollars monthly out of pocket, discontinue and regain most of the weight, or demand that Congress extend coverage. Two of those paths end in the same place.
The Calendar
The statutory exclusion of anti-obesity drugs from Medicare Part D remains on the books. The pricing agreements locked in $245 per month. The Bridge begins tomorrow under demonstration authority that bypasses the exclusion entirely. It expires December 31, 2027. The 2028 presidential election is ten months later.
Eli Lilly and Novo Nordisk accepted a 75 percent discount from list because $245 multiplied by millions of patients exceeds $1,349 multiplied by zero. The government calls it a demonstration because demonstration authority is what CMS has. The eligibility targets the sickest patients, whose savings will be the most dramatic. The eighteen-month window creates a constituency of beneficiaries who will lose their medication if the program ends. The expiration falls in a campaign year.
Demonstrations test whether something works. This one is structured so that ending it would be the proof.